Show simple item record

dc.contributor.authorHerrmann, John E.
dc.contributor.authorWest, Kim
dc.contributor.authorBruns, Matthew
dc.contributor.authorEnnis, Francis A.
dc.date2022-08-11T08:09:10.000
dc.date.accessioned2022-08-23T16:19:46Z
dc.date.available2022-08-23T16:19:46Z
dc.date.issued1990-02-01
dc.date.submitted2017-11-20
dc.identifier.citationJ Infect Dis. 1990 Feb;161(2):180-4.
dc.identifier.issn0022-1899 (Linking)
dc.identifier.pmid2299203
dc.identifier.urihttp://hdl.handle.net/20.500.14038/35127
dc.description.abstractAdministration of rimantadine to mice via drinking water, following a prophylactic dose, reduced lung virus titers by greater than 3 log10 plague-forming units (pfu)/ml but caused only marginal reductions in lung virus titers when therapy was started 8 h after exposure to virus. Mice given rimantadine prophylactically plus therapeutically were resistant to rechallenge with virus at a dose equivalent to that used for the primary infection (50 pfu/mouse) but not to a high dose (1 x 10(5) pfu/mouse). Virus-neutralizing-antibody titers were reduced only by rimantadine treatment, which included prophylaxis, whereas the cytotoxic T lymphocyte (CTL) response was depressed by treatment given with or without prophylaxis. Mice infected with rimantadine-resistant virus had no decrease in CTL or antibody responses when treated with rimantadine. Therefore, the depression in CTL and antibody responses associated with rimantadine treatment appears to be due to a decrease in the amount of viral antigen available or interference with viral antigen processing and not to nonspecific immunosuppressive effects.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=2299203&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://www.jstor.org/stable/30126072
dc.subjectImmunity
dc.subjectImmunology and Infectious Disease
dc.subjectImmunology of Infectious Disease
dc.subjectInfectious Disease
dc.subjectVirology
dc.titleEffect of rimantadine on cytotoxic T lymphocyte responses and immunity to reinfection in mice infected with influenza A virus
dc.typeJournal Article
dc.source.journaltitleThe Journal of infectious diseases
dc.source.volume161
dc.source.issue2
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/infdis_pp/335
dc.identifier.contextkey11095263
html.description.abstract<p>Administration of rimantadine to mice via drinking water, following a prophylactic dose, reduced lung virus titers by greater than 3 log10 plague-forming units (pfu)/ml but caused only marginal reductions in lung virus titers when therapy was started 8 h after exposure to virus. Mice given rimantadine prophylactically plus therapeutically were resistant to rechallenge with virus at a dose equivalent to that used for the primary infection (50 pfu/mouse) but not to a high dose (1 x 10(5) pfu/mouse). Virus-neutralizing-antibody titers were reduced only by rimantadine treatment, which included prophylaxis, whereas the cytotoxic T lymphocyte (CTL) response was depressed by treatment given with or without prophylaxis. Mice infected with rimantadine-resistant virus had no decrease in CTL or antibody responses when treated with rimantadine. Therefore, the depression in CTL and antibody responses associated with rimantadine treatment appears to be due to a decrease in the amount of viral antigen available or interference with viral antigen processing and not to nonspecific immunosuppressive effects.</p>
dc.identifier.submissionpathinfdis_pp/335
dc.contributor.departmentDepartment of Medicine, Division of Infectious Diseases and Immunology
dc.contributor.departmentCenter for Infectious Disease and Vaccine Research
dc.source.pages180-4


This item appears in the following Collection(s)

Show simple item record